scholarly journals Cost-Effectiveness Analysis of Dacomitinib versus Gefitinib in the First-Line Treatment of EGFR-Positive Advanced or Metastatic Non-Small Cell Lung Cancer

2021 ◽  
Vol Volume 13 ◽  
pp. 4263-4270
Author(s):  
Longfeng Zhang ◽  
Na Li ◽  
Maobai Liu ◽  
Bin Zheng ◽  
Zhijuan Wu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cost Effectiveness ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Line Treatment ◽  
Small Cell Lung ◽  
First Line ◽  
Effectiveness Analysis ◽  
First Line Treatment

Cost-Effectiveness Analysis of Atezolizumab Plus Chemotherapy in the First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer

2020 ◽  
Vol 37 (5) ◽  
pp. 2116-2126 ◽  
Author(s):  
Dong Ding ◽  
Huabin Hu ◽  
Mengting Liao ◽  
Yin Shi ◽  
Longjiang She ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cost Effectiveness ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Line Treatment ◽  
Small Cell Lung ◽  
First Line ◽  
Effectiveness Analysis ◽  
First Line Treatment

scholarly journals PCN116 COST-EFFECTIVENESS OF PEMBROLIZUMAB (KEYTRUDA®) PLUS PLATINUM-PEMETREXED FOR FIRST-LINE TREATMENT OF METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER IN FRANCE

2019 ◽  
Vol 22 ◽  
pp. S458
Author(s):  
C. Chouaid ◽  
L. Bensimon ◽  
A. Millier ◽  
E. Clay ◽  
R. Insinga ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cost Effectiveness ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Line Treatment ◽  
Small Cell Lung ◽  
First Line ◽  
First Line Treatment

scholarly journals Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients WithEGFR-Mutated Advanced Non–Small Cell Lung Cancer

JAMA Oncology ◽  
2018 ◽  
Vol 4 (8) ◽  
pp. 1080 ◽  
Author(s):  
Pedro N. Aguiar ◽  
Benjamin Haaland ◽  
Wungki Park ◽  
Pui San Tan ◽  
Auro del Giglio ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cost Effectiveness ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Line Treatment ◽  
Small Cell Lung ◽  
First Line ◽  
First Line Treatment

scholarly journals PCN152 - COST EFFECTIVENESS OF ALECTINIB IN THE FIRST LINE TREATMENT OF ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER IN TURKEY

2018 ◽  
Vol 21 ◽  
pp. S40
Author(s):  
E. Öksüz ◽  
S. Malhan ◽  
L. Yanik ◽  
E. Koc ◽  
E. Erdogan-Ciftci ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cost Effectiveness ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Line Treatment ◽  
Small Cell Lung ◽  
First Line ◽  
Alk Positive ◽  
First Line Treatment
Sign in / Sign up

Export Citation Format

Share Document